CA2369549A1 - Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques - Google Patents

Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques Download PDF

Info

Publication number
CA2369549A1
CA2369549A1 CA002369549A CA2369549A CA2369549A1 CA 2369549 A1 CA2369549 A1 CA 2369549A1 CA 002369549 A CA002369549 A CA 002369549A CA 2369549 A CA2369549 A CA 2369549A CA 2369549 A1 CA2369549 A1 CA 2369549A1
Authority
CA
Canada
Prior art keywords
alkyl
compound according
alkoxy
mono
alkylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369549A
Other languages
English (en)
Inventor
Robert W. Desimone
Alan Hutchison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369549A1 publication Critical patent/CA2369549A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (I), ou les sels non toxiques pharmaceutiquement acceptables de ceux-ci, X, R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, R¿7?, A, B, C, et D représentant des variables définies dans la description. Ces composés peuvent être utilisés pour traiter l'obésité et le diabète. L'invention concerne également des sondes marquées permettant de localiser des récepteurs cellulaires qui interviennent dans la modulation des niveaux glycémiques.
CA002369549A 1999-04-02 2000-03-31 Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques Abandoned CA2369549A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12765699P 1999-04-02 1999-04-02
US28541599A 1999-04-02 1999-04-02
US09/285,415 1999-04-02
US60/127,656 1999-04-02
PCT/US2000/008569 WO2000059887A1 (fr) 1999-04-02 2000-03-31 Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques

Publications (1)

Publication Number Publication Date
CA2369549A1 true CA2369549A1 (fr) 2000-10-12

Family

ID=26825844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369549A Abandoned CA2369549A1 (fr) 1999-04-02 2000-03-31 Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques

Country Status (5)

Country Link
EP (1) EP1165519A1 (fr)
JP (1) JP2002541146A (fr)
AU (1) AU4055400A (fr)
CA (1) CA2369549A1 (fr)
WO (1) WO2000059887A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541145A (ja) * 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体：ブラジキニンｂ２受容体選択性モジュレータ
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
KR20030060904A (ko) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
EP2329839B1 (fr) 2002-01-10 2015-09-16 Imperial Innovations Limited Modification du comportement d'alimentation par GLP-1 et PYY
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2008502721A (ja) 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ***キネシンインヒビターとしての置換キノリン誘導体
KR101170925B1 (ko) 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
RU2007118523A (ru) 2004-10-19 2008-11-27 Новартис Вэксинс Энд Диагностикс Инк. (Us) Производные индола и бензимидазола
ES2377526T3 (es) 2005-01-10 2012-03-28 Cortendo Ab (Publ) 2S,4R ketoconazol para el tratamiento de la diabetes, el síndrome metabólico y otras afecciones
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
ZA200902127B (en) 2006-10-02 2010-07-28 Cortendo Invest Ab Ketoconazole enantiomer in humans
CA2668661A1 (fr) 2006-11-13 2008-05-29 Novartis Ag Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
EP1935420A1 (fr) 2006-12-21 2008-06-25 Merck Sante Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1
MX2009007260A (es) 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
ES2369315T3 (es) * 2007-06-01 2011-11-29 F. Hoffmann-La Roche Ag Derivados de piperidina-amida.
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
EP2358200A4 (fr) 2008-11-17 2012-05-16 Merck Sharp & Dohme Amines bicycliques substituées pour le traitement du diabète
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2011011508A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés d’oxazépine benzofusionnés en tant qu’inhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase
US8765728B2 (en) 2009-11-16 2014-07-01 Mellitech [1,5]-diazocin derivatives
CA2784799C (fr) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certains inhibiteurs de la dipeptidylpeptidase
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
WO2014045266A1 (fr) 2012-09-24 2014-03-27 Ulf Eriksson Traitement de diabète de type 2 et d'états apparentés
WO2020074958A1 (fr) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Lévokétoconazole pour le traitement de l'hyperplasie surrénale congénitale et de l'aldostéronisme primaire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3063162B2 (ja) * 1995-12-28 2000-07-12 藤沢薬品工業株式会社 ベンズイミダゾール誘導体

Also Published As

Publication number Publication date
WO2000059887A1 (fr) 2000-10-12
EP1165519A1 (fr) 2002-01-02
JP2002541146A (ja) 2002-12-03
AU4055400A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
US6271241B1 (en) Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
CA2369549A1 (fr) Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques
US11401258B2 (en) Isoquinoline derivatives and use thereof
EP3810587B1 (fr) Indolsulfonamides alkoxypyridinyl substitués
JP2019031531A (ja) アザスピロ［４．５］デカン誘導体及びその使用
US7160879B2 (en) Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
US10793531B2 (en) Triazole derivatives and their use as PDE4 activators
AU2002223802A1 (en) Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
US6906075B2 (en) Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
Murakami et al. 1, 3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists
WO2008052072A9 (fr) Composés destinés au traitement de la douleur et procédés de dépistage à cet effet
Hirose et al. Discovery of novel 5-oxa-2, 6-diazaspiro [3.4] oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus
JP2021520340A (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
JP2019532929A (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
US7456201B2 (en) Pharmaceutically active compounds and methods of use
EP1165517A1 (fr) N-benzimidazolylmethyl- et n-indolylmethyl-benzamides et leur application comme modulateurs de corticoliberine
JP2002541151A (ja) アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体：ＧＡＢＡａ受容体の選択的修飾物質
Sun et al. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists
US20010049447A1 (en) Mibefradil analogues and their use
US6281237B1 (en) N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6482844B1 (en) 1-benzylimidazole derivatives
US20040087561A1 (en) Treatment of sexual dysfunction
US20050239791A1 (en) Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
US20040122046A1 (en) NPY-5 antagonists
JP2005529160A (ja) 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物

Legal Events

Date Code Title Description
FZDE Dead